Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROOF study of personalized chemotherapy selection from pleural fluid tumor cell drug profiling
NL-OMON28874Phase 2Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine, gemcitabine, pemetrexed, oxaliplatin, doxorubicin and 2 more in pleural mesothelioma and non-small cell lung cancer (NSCLC), sponsored by Netherlands Cancer Institute. Primary endpoint: Accuracy of the drug profiling method. Planned start Jun 2014; status: not yet recruiting.
02
Drugs
vinorelbinegemcitabinepemetrexedoxaliplatindoxorubicin
03
Conditions
pleural mesotheliomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON28874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28874.